After A Record Year, China Healthcare IPOs Have Endured A Tough 2011
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - Last year was a banner year for China's life sciences companies, with 34 new stock offerings globally that raised $6.9 billion from the capital market. But the first half of 2011 has been a disappointment across healthcare sectors for Chinese firms
You may also be interested in...
Innovation, Prevention And Technology Transfer - China Releases Five-Year Plan For Medical Technology
Likely winners include new drug, medical device and traditional Chinese medicine manufacturers, according to analysts.
Innovation, Prevention And Technology Transfer - China Releases Five-Year Plan For Medical Technology
Likely winners include new drug, medical device and traditional Chinese medicine manufacturers, according to analysts.
Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q2 2011
Of the $6.3 billion total raised, 32% was from China distributor Shanghai Pharmaceuticals' $1.99 billion IPO - not only Q2's biggest financing, but also the second-largest pharma IPO of all time. Six of the 26 completed mergers were done to gain access to emerging markets, most notably, Takeda's $13.7 billion buy of Nycomed, almost half of the total $27.9 billion spent on pharma acquisitions this quarter. Q2's largest alliance was Vertex's in-licensing of Alios BioPharma's preclinical HCV nucleotide analogues, a deal that could be worth up to $775 million in up fronts and development milestones.